top of page
Michaël Hocquemiller is scientific director at Lysogene. He has 15 years of experience in AAV gene therapy development focused on neurodegenerative diseases. Dr. Hocquemiller has co-led the Phase 1 clinical trial in MPS IIIA, as well as designing drug candidates and pre-clinical work that have now advanced into clinical development. Before joining Lysogene, Dr. Hocquemiller worked as a research scientist at the Pasteur Institute focused on neurophysiopathology and gene therapy of Lysosomal Storage Diseases.
bottom of page